BJMO - volume 11, issue 8, december 2017
L. Decoster MD, PhD, K. Vekens MD, S. Mignon MD, D. Schallier MD, PhD, J. De Grève MD, PhD
Antibodies against programmed cell death-1 (PD-1) and its ligand (PD-L1) have become standard-of-care in the second-line treatment for advanced non-small cell lung cancer after failure of first-line chemotherapy. The observed durable responses as well as the favourable toxicity profile have moved these agents to first-line studies for advanced non-small cell lung cancer. In tumours with high PD-L1 expression, pembrolizumab is registered as the preferred first-line treatment. Further studies are currently focusing on combination strategies. The major future challenge will be selecting the optimal treatment strategy for the patient.
(BELG J MED ONCOL 2017;11(8):380–385)
Read moreBJMO - volume 11, issue 2, march 2017
L. Decoster MD, PhD, C. Kenis RN, PhD
The 2016 annual conference of the International Society of Geriatric Oncology took place in Milan, Italy from November 17–19th. More than 450 delegates from 42 countries with a special interest in the care for older patients with cancer attended this conference. The meeting provided an overview of current advances in geriatric oncology.
(BELG J MED ONCOL 2017;11(2):78–80)
Read moreBJMO - 2017, issue 3, february 2017
L. Decoster MD, PhD, C. Kenis RN, PhD, J. Flamaing , P.R. Debruyne , I. De Groof , C. Focan MD, PhD, F. Cornélis MD, V. Verschaeve MD, K. Vanoverbeke , Y. Libert , S. Luce , N. Nols , H. van den Bulck , J.C. Goeminne MD, K. Geboers , J.P. Lobelle , M. Lycke , K. Milisen PhD, H. Wildiers MD, PhD, A. Baitar
BJMO - 2017, issue 3, february 2017
R.B. Shahi MSc, B. Caljon , S. De Brakeleer PhD, L. Decoster MD, PhD, C. Fontaine MD, L. Vanacker MD, M. Vanhoeij , I. Pauwels , M-L. Bonduelle , S. Van Dooren PhD, D. Croes , E. Teugels PhD, J. De Grève MD, PhD
BJMO - volume 10, issue 7, november 2016
J. De Grève MD, PhD, L. Decoster MD, PhD, R.B. Shahi MSc, C. Fontaine MD, L. Vanacker MD, I. Pauwels , E. Denayer MD, PhD, S. De Brakeleer PhD, E. Teugels PhD
Inhibition of Poly (ADP-ribose) polymerase 1 has relatively recently entered the clinic. The ground-breaking drug both scientifically and clinically was olaparib, but several other PARP inhibitors are in development. This treatment is the first to therapeutically exploit mutant recessive cancer genes. In this review we discuss the discovery of this treatment, the preclinical and clinical studies, as well as some future perspectives.
(BELG J MED ONCOL 2016;10(7):263–275)
Read moreBJMO - volume 10, issue 3, may 2016
L. Decoster MD, PhD
Report from the 2015 Annual Meeting of the International Society of Geriatric Oncology (SIOG).
The 2015 Annual Conference of the International Society of Geriatric Oncology took place in Prague, Czech Republic from November 12–14th. More than 400 delegates with a special interest in the care for older patients with cancer attended this conference, including medical oncologists, geriatricians, surgeons, nurses and other professional health care workers. The meeting provided an overview of current advances in geriatric oncology domains.
(BELG J MED ONCOL 2016;10(3):108–9)
Read moreBJMO - volume 8, issue 5, november 2014
L. Decoster MD, PhD
The 2014 annual meeting of the European Society for Medical Oncology (ESMO) featured a number of interesting studies in endocrine and neuroendocrine oncology. This report will first focus on two presentations regarding lenvatinib in the treatment of thyroid cancers. In addition to this, the final OS of the RADIANT-3 study, evaluating everolimus in patients with advanced pancreatic neuroendocrine tumours (NET), will be summarized. The last part of the report will focus on the molecular profiling of NETs and discusses a study assessing the quality of life in NET patients using lanreotide autogel.
(BELG J MED ONCOL 2014;8(4):163–5)
Read more
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
